1. Poly(ADP-Ribose) Polymerase 1 (PARP1) Overexpression in Human Breast Cancer Stem Cells and Resistance to Olaparib.
- Author
-
Gilabert, Marine, Launay, Simon, Ginestier, Christophe, Bertucci, François, Audebert, Stéphane, Pophillat, Mathieu, Toiron, Yves, Baudelet, Emilie, Finetti, Pascal, Noguchi, Tetsuro, Sobol, Hagay, Birnbaum, Daniel, Borg, Jean-Paul, Charafe-Jauffret, Emmanuelle, and Gonçalves, Anthony
- Subjects
POLY(ADP-ribose) polymerase ,BREAST cancer treatment ,GENE expression ,PIPERAZINE ,CANCER stem cells ,DRUG resistance in cancer cells ,TUMOR markers ,ONCOLOGY - Abstract
Background: Breast cancer stem cells (BCSCs) have been recognized as playing a major role in various aspects of breast cancer biology. To identify specific biomarkers of BCSCs, we have performed comparative proteomics of BCSC-enriched and mature cancer cell populations from the human breast cancer cell line (BCL), BrCA-MZ-01. Methods: ALDEFLUOR assay was used to sort BCSC-enriched (ALDH+) and mature cancer (ALDH−) cell populations. Total proteins were extracted from both fractions and subjected to 2-Dimensional Difference In-Gel Electrophoresis (2-D DIGE). Differentially-expressed spots were excised and proteins were gel-extracted, digested and identified using MALDI-TOF MS. Results: 2-D DIGE identified poly(ADP-ribose) polymerase 1 (PARP1) as overexpressed in ALDH+ cells from BrCA-MZ-01. This observation was confirmed by western blot and extended to four additional human BCLs. ALDH+ cells from BRCA1-mutated HCC1937, which had the highest level of PARP1 overexpression, displayed resistance to olaparib, a specific PARP1 inhibitor. Conclusion: An unbiased proteomic approach identified PARP1 as upregulated in ALDH+, BCSC-enriched cells from various human BCLs, which may contribute to clinical resistance to PARP inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF